Related Experiment Video
Updated: Sep 24, 2025
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases
Benjamin Steren1, Barbara Burtness2, Aarti Bhatia3
1Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven.
Ophthalmic Plastic and Reconstructive Surgery
|May 3, 2022
Summary
Cemiplimab demonstrates high efficacy in treating orbital squamous cell carcinoma, with 82% of patients achieving a complete response. This immune checkpoint inhibitor offers a globe-sparing alternative to surgery for this rare cancer.
Area of Science:
- Ophthalmology
- Oncology
- Immunology
Background:
- Orbital squamous cell carcinoma (OSCC) is a rare malignancy.
- Treatment options for OSCC can be disfiguring, often requiring orbital exenteration.
- Novel therapeutic approaches are needed to improve outcomes and preserve ocular function.
Purpose of the Study:
- To review the demographics, clinical features, and treatment response of patients with orbital squamous cell carcinoma (OSCC) treated with cemiplimab.
- To evaluate cemiplimab as a potential globe-sparing therapy for OSCC.
Main Methods:
- Retrospective, multi-institutional case series.
- Analysis of patient demographics, clinical characteristics, and treatment details.
- Evaluation of treatment response and adverse events associated with cemiplimab.
Main Results:
- Eleven patients with OSCC were treated with cemiplimab (350 mg every 3 weeks).
- Patients received an average of 11.2 cycles of treatment.
- Nine out of eleven patients (82%) achieved a complete response.
- No significant side effects requiring treatment discontinuation were observed.
Conclusions:
- Cemiplimab is an effective treatment for orbital squamous cell carcinoma.
- This immune checkpoint inhibitor offers a promising globe-sparing alternative to orbital exenteration.
- Further research into immunotherapy for OSCC is warranted.
